Aurion Biotech Information for Proposed IPO

Aurion Biotech (AURN) has filed for a proposed IPO.

The corporate describes itself as: “We’re a clinical-stage biotechnology firm dedicated to growing and commercializing disease-modifying, regenerative therapies to revive imaginative and prescient to thousands and thousands of sufferers worldwide. We’re advancing a single administration, allogeneic cell remedy to deal with imaginative and prescient loss on account of corneal endothelial illnesses. In Japan, our first-generation cell remedy product, HCEC-1, obtained regulatory and reimbursement approval, and launched commercially in September 2024 beneath the marketed identify Vyznova. Our next-generation product candidate, AURN001, is an improved formulation designed to be mechanistically similar to Vyznova and to supply enhanced advantages, together with manufacturing scalability and prolonged shelf life. We consider AURN001 has the potential to function a first-line remedy for sufferers with corneal edema secondary to corneal endothelial dysfunctions. AURN001 has been developed leveraging knowledge generated globally throughout 5 accomplished scientific trials in 154 procedures in 130 topics, together with 4 trials evaluating HCEC-1 and one trial evaluating AURN001. Throughout these accomplished trials, topics skilled clinically significant and sustained enhancements in anatomical and useful measures of corneal well being, central corneal thickness (“CCT”) and finest corrected visible acuity (“BCVA”), respectively. As well as, we have now accomplished enrollment and dosed 97 topics in a Part 1/2 scientific trial for AURN001 in the US and Canada, and 12-month knowledge from this trial is predicted within the second half of 2025.”

J.P. Morgan, BofA Securities, Piper Sandler and Wells Fargo (NYSE:WFC) Securities will function underwriters.